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Introduction: Pseudomonas aeruginosa behaves as an opportunistic 
pathogen involved in hospital infections, with high capacity to generate 
resistance to antibiotic treatment. The interpretative reading of the 
antibiogram makes possible inferring these resistance mechanisms and 
establishing appropriate antibiotic treatment.
Objective: The interpretative reading of the antibiogram seeks 
to infer the resistance phenotype of P. aeruginosa at Fundación 
Hospital de la Misericordia (HOMI, by its acronym in Spanish) 
between 2006 and 2014.
Materials and methods: Descriptive cross-sectional study where a 
search of positive antibiogram reports for P. aeruginosa was performed. 
The resistance phenotype was deduced based on the interpretative 
reading of the antibiogram.
Results: A sample of 463 positive antibiograms for P. aeruginosa 
was obtained; these samples were taken from children aged 0 
to 17, showing a higher prevalence among infants and toddlers. 
The antibiograms mainly came from male subjects (62.2%). The 
most frequent hospitalization services were: PICU —pediatric 
intensive care unit— (30.2%) and general hospitalization (27.3%). 
The most common sources of isolation were: blood (24.4%) 
and urine (23.8%). 11 phenotypes were characterized, being the 
most common: natural phenotype (63.2%), loss of porin OprD 
(5.7%) and partial and full AmpC derepression (8.4% and 8.2%, 
respectively).
Conclusion: Isolation of P. aeruginosa at HOMI predominantly shows 
a natural phenotype. The interpretative reading of the antibiogram 
allowed inferring 11 phenotypes.
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| Resumen |
Introducción. Pseudomonas aeruginosa se comporta como un 
patógeno oportunista implicado en infecciones intrahospitalarias y 
tiene alta capacidad de generar resistencia al manejo antibiótico. 
La lectura interpretada del antibiograma permite inferir estos 
mecanismos de resistencia y establecer el antibiótico más apropiado. 
Objetivo. La lectura interpretada del antibiograma busca inferir el 
fenotipo de resistencia de P. aeruginosa en la Fundación Hospital 
de la Misericordia (HOMI) entre 2006 y 2014. 
Materiales y métodos. Estudio descriptivo de corte transversal 
donde se realizó la búsqueda de informes de antibiogramas positivos 
para P. aeruginosa y se dedujo el fenotipo de resistencia según la 
lectura interpretada del antibiograma. 
Resultados. Se obtuvo una muestra de 463 antibiogramas positivos 
para P. aeruginosa aisladas de niños entre 0 y 17 años, con predominio 
en lactantes y preescolares de género masculino (62.2%). Los servicios 
de hospitalización más frecuentes fueron unidad de cuidado intensivo 
pediátrico (30.2%) y hospitalización general (27.3%). Los sitios de 
aislamiento más frecuentes fueron sangre (24.4%) y orina (23.8%). 
Se caracterizaron en total 11 fenotipos, los más frecuentes fueron 
natural (63.2%), pérdida de porina OprD (5.7%) y desrepresión 
parcial (8.4%) y total (8.2%) de AmpC. 
Conclusión. Los aislamientos de P. aeruginosa en el HOMI tienen 
de manera predominante un fenotipo natural. La lectura interpretada 
del antibiograma permitió inferir 11 fenotipos.
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Introduction
Pseudomonas aeruginosa is a Gram negative, non-fermenting bacillus 
that has the ability to survive on inert surfaces and produce biofilms 
(1,2); this feature allows survival in hospital environments and growth 
in standard culture media, since their nutritional requirements are few 
(3). It has a genome with 6.3 million base pairs, which encodes 5 570 
genes, and is rich in virulence factors (4).
In addition, P. aeruginosa is a pathogen involved in nosocomial 
infections associated with high morbidity and mortality rates, 
prolonged hospital stay and higher treatment costs. It also behaves 
as an opportunistic nosocomial agent, especially in patients with risk 
factors such as cystic fibrosis, prolonged hospitalization in critical 
care units and immunodeficiency (4).
Within the studied P. aeruginosa phenotypes, the wild or natural is 
characterized by being sensitive to carboxypenicillins, ureidopenicillins, 
ceftazidime, cefepime, cefoperazone, aztreonam and carbapenems 
(1), but it is also recognized by the intrinsic expression of resistance 
to a wide range of antibiotics and the development of mechanisms of 
antimicrobial resistance during operation via plasmids and integrons 
or mutations in the gene coding (5); this provides resistance to usually 
active compounds (6).
The intrinsic resistance of this bacteria is given by the low 
permeability of the outer membrane cell, the presence of inducible 
chromosomal β-lactamases (AmpC) and MexAB-OprM efflux 
system expression (7). Some strains can produce other β-lactamases 
such as oxacilinases (OXA), extended spectrum β-lactamases 
(ESBL) or carbapenemases (3). Based on the amino acid sequence, 
the used energy source and the substrate, efflux systems have been 
characterized in five superfamilies (5,8). 
Another important mechanism is the aminoglycoside resistance, 
which occurs due to the enzymatic modification of antibiotics and 
affects the affinity of P. aeruginosa 30s ribosomal subunit. The involved 
enzymes are phosphoryltransferase (APH), adenyltransferases or 
nucleotidyltransferase (AADoANT) and acetyltransferase (AAC); 
methylation cases are also described in the 16s subunit of ribosomal 
RNA (9,10). Fluoroquinolone resistance is caused by changes in the 
DNA gyrase (affectation of genes gyrA and parC) and topoisomerase 
IV and active efflux systems (11).
This bacterium is inherently resistant to penicillin, aminopenicillins 
—β-lactamases inhibitors—, first and second generation 
cephalosporins, ceftriaxone, cefotaxime, oral third generation 
cephalosporins, chloramphenicol, nitrofurantoin, sulfonamides, 
trimethoprim, tetracyclines, novobiocin and nalidixic acid (1). 
Although there are cases of resistance to colistin, these mechanisms 
are still unknown and have been linked to alterations in the regulatory 
protein PmrA or outer membrane protein OprH; however, most 
strains remain sensitive (12). 
In recent decades, there has been a global spread of bacterial 
resistance, considered as a growing and complex emergency, which 
was declared a public health problem in 1998 by the World Health 
Organization (WHO) (13).
The use of broad-spectrum antimicrobials has caused the onset of 
multidrug-resistant strains and, despite the importance of the mechanisms 
of resistance and their continuous identification, few antibacterial 
agents have been developed, leaving a limited number of therapeutic 
options for the management of patients with P. aeruginosa (14).
The techniques used for identification of resistance mechanisms 
include phenotypic and genotypic or geneticoes. The first is based 
on the sensitivity to antibiotics of different bacteria and its main 
objective is to guide the physician when deciding the ideal antibiotic 
treatment according to patient clinic and history. This technique is 
performed using the antibiogram, where the sensitivity of bacteria 
to different antibiotics is obtained in vitro, thus predicting efficacy 
in vivo through a qualitative or quantitative result, which will 
suggest whether the bacteria is sensitive or resistant to an antibiotic 
and will also determine minimum inhibitory concentration (MIC).
Based on MIC values established by various committees that 
take into account the microbiological, pharmaceutical and clinical 
efficacy properties, some breakpoints are set on susceptibility tests 
and interpretation is defined as suceptible, intermediate or resistant. 
These committees include the Clinical & Laboratory Standards 
Institute in the U.S., which is the basis for this study.
Based on the results of the sensitivity tests, the interpretative 
reading of the antibiogram was performed; this tool was described by 
Patrice Courvaline in 1992, and takes into account three foundations: 
a) phenotypic characterization of resistance according to the study 
of sensitivity regarding antibiotic groups of the same family, b) 
deduction based on the corresponding resistance phenotype of the 
involved biochemical mechanism, and c) inference of the phenotype 
previously established from the resistance mechanism deduced (1,15)
The Fundación HOMI is an exclusively pediatric institution 
with 305 beds: 15 beds for the pediatric intensive care unit 
(PICU), 24 for pediatric intermediate care, 12 for the neonatal 
intensive care unit (NICU), 49 for the oncohematology service, 6 
for hematopoietic stem cell transplantation, 12 for the burn unit and 
the rest for general pediatrics. This capability makes the institution 
a center of national reference that treats patients at high risk of 
infection with P. aeruginosa.
The institutional report of 2013, provided by the Group for 
the Control of Antimicrobial Resistance in Bogotá (GREBO, by 
its acronym in Spanish), reported a frequency of infection by P. 
aeruginosa in PICU of 7% in a total of 250 isolates and ranking sixth 
among other germs; in the non-ICU area, the infection rate was also 
7% for a total of 804 isolates, ranking fifth. The same report showed 
antibiotic resistance to piperacillin tazobactam of 8.2%, cefepime of 
6.8%, imipenem of 14.1% and meropenem 11.4%.
This paper seeks to understand the resistance profiles of isolates 
of P. aeruginosa and to infer the resistance mechanisms prevalent 
in the institution in order to design control measures to expand and 
optimize the antimicrobial management through knowledge of 
institutional susceptibility to this germ.
Materials and methods
This was a descriptive cross-sectional study.
Definition of study subjects
Population: all patients hospitalized in HOMI during 2006 and 2014 
with antibiotic susceptibility reports testing positive for P. aeruginosa.
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Sample: all antibiograms obtained.
Unit of analysis: antibiograms report.
Inclusion criteria: antibiograms reports testing positive for P. 
aeruginosa in patients hospitalized in HOMI during 2006 and 2014, 
identified through the Vitek (Biomereux, France) automated system.
Exclusion criteria: incomplete antibiograms reports testing positive 
for P. aeruginosa in hospitalized patients and reports of patients 
evaluated by outpatient consultation in HOMI.
Description of the interventions
Susceptibility testing reports were identified, and the variables 
sex, age, date and place of hospitalization of patients at the time of 
sampling were considered.
When susceptibility testing reports were identified, an interpretive 
reading was made and possible mechanisms of bacterial resistance 
were suggested.
Procedures
1. Identification of antibiograms: positive reports were sought 
in the WHONET 5.6® database.
2. Deduction of the resistance mechanism: through the antibiogram, 
the analysis of bacterial phenotype and the identification of 
possible mechanisms of resistance were conducted; for analyzing 
the resistance profiles, the WHONET 5.6® software was used, and 
for interpretation of the criteria, the CLSI 2012 standards were 
taken into account (16).
Sensitivity tests were analyzed for five antibiotics: piperacillin 
tazobactam (PTZ), cefepime (FEP), ceftazidime (CAZ), imipenem 
(IPM) and meropenem (MEM).The interpreted reading was based 
on the paper by Vila et al. (1), which was modified taking into 
account the antibiogram report obtained at HOMI (Table 1 and 2).
Table 1. Enzymatic resistance mechanisms.
Resistance phenotypes
PTZ CAZ CEF IMP MER
Inferred resistance 
mechanism
S S S S S Natural
I I S/I S S Partial AmpC derepression 
R R I/R S S Total AmpC derepression
S S S/I S S
Class A β-lactamase- Non-
ESBL
S/I R R S S Class A β-lactamase- ESBL
S R R I/R I/R GES-2
I/R S R S S OXA-1, OXA-31
R R I/R S S OXAs- ESBL
R R R I/R I/R Metallo-β- lactamase
PTZ: piperacillin tazobactam; CAZ: ceftazidime; CEF: cefepime; IMP: imipenem; 
MER: meropenem; R: resistant; S: suceptible; I: intermediate. Source: (1).
Table 2. Deficiency of porins and active efflux systems.
Resistance phenotypes 
PTZ CAZ CEF IMP MER Resistance mechanism 
S S S R I Porin OprD Loss
I/R I/R I/R S I MexAB-OprM system
I/R I/R R S S MexCD-OprJ system
I/R I/R I/R R I MexEF-OprN system
I/R I/R I/R S S MexXY-OprM system
PTZ: piperacillin tazobactam; CAZ: ceftazidime; CEF: cefepime; IMP: imipenem; 
MER: meropenem R: resistant; S: suceptible; I: intermediate. Source: (1).
Statistical analysis 
A descriptive analysis of absolute and relative frequencies for 
qualitative and quantitative variables was performed. For the latter, 
central tendency and dispersion measures were calculated. 
Ethical considerations
Since the study is observational, it was classified as an investigation 
without risk as stipulated in Resolution 8430 of 1993 by the 
Ministry of Health (17). The protocol was taken to the Scientific 
Research and Teaching Unit of the Department of Pediatrics at 
Universidad Nacional de Colombia and to the Ethics Committee of 
Fundación HOMI, where it was evaluated and approved.
Results
During the six years of the study, 463 reports were obtained for 
positive antibiograms of P. aeruginosa strains, mostly in male 
patients (61.6%). 62.9% of the samples were obtained from lactating 
patients, 15.1% from preschool children, 14.5% from schoolchildren 
and 7.6% from adolescents. The most frequent isolation sites were 
blood (25.5%), urine (20.7%) and tracheobronchial secretion 
(13.8%) (Table 3). The most frequent isolation area in the 
hospital was the intensive care unit (29.4%), followed by general 
hospitalization (28.1%) and emergency room (16.6%). The most 
common phenotype was natural (66.5%), followed by partial and 
full AmpC derepression (8.4% and 8.2%) and OprD porin loss (6%).
The resistance rates found for each antibiotic by hospital area 
were: meropenem in PICU, 7%; in NICU, 3.5%, and in ICU, 8.4%. 
Cefepime in PICU was 11.9%; in NICU, 3.5%, and non-ICU, 1.4%. 
Piperacillin tazobactam in PICU was 12.1%; no resistance was 
found in NICU, and in ICU, 14.3%.
Table 4 shows that the most common phenotype in critical care 
areas was natural (57%), followed by porin OprD loss (12%) and 
partial and total AmpC derepression (9.5% and 8.9%, respectively). 
In non-critical hospital areas, natural phenotype was the most 
frequent (71.5%), followed by partial and total AmpC derepression 
(7.9% each) and metallo-β-lactamase (6.6%). 
Table 5 shows that the most common phenotype was natural in all 
critical units, being predominant in pediatric intensive care (56.6%). 
In general, the most common phenotypes were porin OprD loss and 
AmpC derepression in the PICU; partial derepression of AmpC and 
Class A β-lactamase non-ESBLs in NICU; total and partial AmpC 
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derepression in the oncology unit; metallo-β-lactamase, followed by 
total or partial AmpC derepression and porin OprD loss in general 
hospitalization; metallo-β-lactamase and partial AmpC derepression 
in hospitalization for surgery; total AmpC derepression and OXA-1, 
OXA-31 in the burn unit, and total and partial AmpC derepression 
and porin OprD loss in emergency room.
Table 3. Distribution of isolates of Pseudomonas aeruginosa, according to 
sample type, service and resistance phenotype, 2006-2014.









Cerebrospinal fluid 9 1.9
Bone 9 1.9
Others 4 0.9
Pleural fluid 2 0.4
Hospital isolation 
area
Pediatric critical care units 136 29.4
General hospitalization 130 28.1
Emergency room 77 16.6
Surgery 57 12.3
Oncology 25 5.4
Neonatal critical care units 22 4.8
Burn unit 15 3.2
Hematopoietic transplant unit 1 0.2
Phenotype
Natural 308 66.5
Partial AmpC derepression 39 8.4
Total AmpC derepression 38 8.2
Porin OprD loss 28 6.0
Metallo-β-lactamase 26 5.6
Class A β-lactamase- No ESBL 15 3.2
Class A β-lactamase- ESBL 3 0.6
OXA-1, OXA-31 2 0.4
MexEF-OprN system 2 0.4
GES-2 1 0.2
MexXY-OprM system 1 0.2
Total 463 100
Source: Own elaboration based on the data obtained in the study.









n % n % n %
Phenotype
Natural 90 57.0 218 71.5 308 66.5
Porin OprD loss 19 12.0 9 3.0 28 6.0
Partial AmpC 
derepression
15 9.5 24 7.9 39 8.4
Total AmpC 
derepression
14 8.9 24 7.9 38 8.2
Metallo-β-lactamase 10 6.3 16 5.2 26 5.6
Class A β-lactamase- 
No ESBL
7 4.4 8 2.6 15 3.2
Class A β-lactamase- 
ESBL
1 0.6 2 0.7 3 0.6
GES-2 1 0.6 0 0.0 1 0.2
MexEF-OprN system 1 0.6 1 0.3 2 0.4
OXA-1, OXA-31 0 0.0 2 0.7 2 0.4
MexXY-OprM system 0 0.0 1 .3 1 0.2
Total 158 100 305 100 463 100
Source: Own elaboration based on the data obtained in the study.
Table 6 shows that the natural phenotype predominated in all 
samples except in pleural fluid, where derepression of AmpC and 
metallo-β-lactamase phenotypes were predominant. Skin, urine and 
blood presented natural phenotype, followed by AmpC derepression 
and metallo-β-lactamases in the two last tissues. In tracheobronchial 
secretion and blood, after the natural phenotype, the most frequent 
was porin OprD loss, and in catheter, natural phenotype was 
followed by class A β-lactamase non-ESBL phenotype.
  
Discussion
P. aeruginosa is found repeatedly in patients within a specific context 
—hospitalized, immunocompromised, treated with broad-spectrum 
antibiotics, carriers of instrumented or prosthetic materials, patients 
with severe infection, prolonged hospitalization and presence of cross 
infections— so it constitutes the cause of hospital-acquired infections 
(HAI) (6). The prognosis of infection, compared with other agents, 
is reserved because the antibiotic treatment may not be effective in 
many cases, even in patients treated properly and early (3).
This bacterium is a lethal pathogen that is credited with 35% 
mortality in bacteremia and 69% in ventilator-associated pneumonia 
(18). This high mortality rate represents the potential to improve 
therapies and interventions. 
In this study, the collected sample is important since it found that 
male infants are the patients with greater isolation of the pathogen; 
such isolation was seen in blood, urine and tracheobronchial 
secretion, and the most common hospital areas were PICU, general 
hospitalization and emergency department. 
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Natural 77 56.6 13 59.1 19 76 1 100 93 71.5 36 63.2 11 73.3 58 75.30 308 66.50
Porin OprD loss 19 14 0 0 1 4 0 0 2 1.5 3 5.3 0 0 3 3.90 28 6.00
Total AmpC derepression 13 9.6 1 4.5 3 12 0 0 8 6.2 3 5.3 3 20 7 9.10 38 8.20
Partial AmpC derepression 11 8.1 4 18.2 2 8 0 0 12 9.2 6 10.5 0 0 4 5.20 39 8.40
Metallo-β-lactamase 9 6.6 1 4.5 0 0 0 0 6 4.6 8 14 0 0 2 2.60 26 5.60
Class A β-lactamase- 
Non- ESBL
4 2.9 3 13.6 0 0 0 0 5 3.8 1 1.8 0 0 2 2.60 15 3.20
Class A β-lactamase- ESBL 1 0.7 0 0 0 0 0 0 2 1.5 0 0 0 0 0 0.00 3 0.60
GES-2 1 0.7 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 1 0.20
MexEF-OprN system 1 0.7 0 0 0 0 0 0 1 0.8 0 0 0 0 0 0.00 2 0.40
OXA-1, OXA-31 0 0 0 0 0 0 0 0 0 0 0 0 1 6.7 1 1.30 2 0.40
MexXY-OprM system 0 0 0 0 0 0 0 0 1 0.8 0 0 0 0 0 0.00 1 0.20
Total 136 100 22 100 25 100 1 100 130 100 57 100 15 100 77 100 463 100
Source: Own elaboration based on the data obtained in the study. 

































































Natural 40 62.5 45 56.3 7 77.8 18 72 23 88.5   4 44.4 74 62.7 76 79.2 19 63.3 2 50 308 66.50 
Partial AmpC 
derepression
8 12.5 8 10 1 11.1 1 4   1 50 2 22.2 8 6.8 7 7.3 3 10   39 8.40 
Total AmpC 
derepression








  1 1.3           2 1.7       3 0.60 
GES-2               1 0.8       1 0.20 
OXA-1, OXA-31 1 1.6 1 1.3                   2 0.40 
Metallo-β-
lactamase
5 7.8 4 5       1 50 3 33.3 7 5.9 5 5.2 1 3.3   26 5.60 
Porin OprD loss 5 7.8 9 11.3   1 4       10 8.5 2 2.1 1 3.3   28 6.00 
MexEF-OprN 
system
  1 1.3               1 3.3   2 0.40 
MexXY-OprM 
system
                1 1     1 0.20 
Total 64 100 80 100 9 100 25 100 26 100 2 100 9 100 118 100 96 100 30 100 4 100 463 100
Source: Own elaboration based on the data obtained in the study.
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Discussion
P. aeruginosa is found repeatedly in patients within a specific context 
—hospitalized, immunocompromised, treated with broad-spectrum 
antibiotics, carriers of instrumented or prosthetic materials, patients 
with severe infection, prolonged hospitalization and presence of cross 
infections— so it constitutes the cause of hospital-acquired infections 
(HAI) (6). The prognosis of infection, compared with other agents, 
is reserved because the antibiotic treatment may not be effective in 
many cases, even in patients treated properly and early (3).
This bacterium is a lethal pathogen that is credited with 35% 
mortality in bacteremia and 69% in ventilator-associated pneumonia 
(18). This high mortality rate represents the potential to improve 
therapies and interventions. 
In this study, the collected sample is important since it found that 
male infants are the patients with greater isolation of the pathogen; 
such isolation was seen in blood, urine and tracheobronchial 
secretion, and the most common hospital areas were PICU, general 
hospitalization and emergency department. 
The most common phenotype in all areas and isolates was natural, 
being more frequent in non-critical areas. However, other 10 phenotypes, 
including partial or complete AmpC derepression (resistance to narrow 
spectrum aminopenicillins and cephalosporins inducible by cefoxitin 
and imipenem, sensitive only to carbapenems, resistance to piperacillin 
tazobactam) porin OprD loss (resistance to carbapenems), metallo-
β-lactamase (carbapenemases), class a β-lactamase non-ESBL and 
ESBL (resistance to carboxypenicillins, ureidopenicillins, ceftazidime, 
cefepime, cefpirome and aztreonam), OXA-1, OXA-31 (no inhibition 
by clavulanic acid, sulbactam or tazobactam, with hydrolytic activity 
in ceftazidime, cefepime, cefpirome and aztreonam), GES-2, and 
MexEF-OprN and MexXY-OprM systems (possible involvement in the 
activity of beta-lactams, carbapenems, fluoroquinolones, macrolides, 
tetracyclines, chloramphenicol, novobiocin and lincomycin) (8).
It is noteworthy that PICU, a place where the use of carbapenems 
is high, the loss of porin OprD and AmpC derepression were the most 
frequent resistance mechanisms. In the oncology unit, the service in 
which the use of carbapenems is restricted to unstable patients, total 
and partial derepression of AmpC were more frequent.
In general hospitalization services, the most common phenotype 
was metallo-β-lactamase, followed by partial AmpC derepression 
and OprD porin loss, which can be related to the pressure for 
selection to which patients treated there are subjected, including 
oncohematology and rheumatology undergoing immunosuppression. 
In surgery hospitalization, metallo-β-lactamase and partial AmpC 
derepression were more frequent, which can be correlated with the 
arrival of critically ill patients who require a surgical procedure 
for improvement, prior to the empirical use of broad-spectrum 
antibiotics, leading to selection pressure.
In the burn unit, the phenotype AmpC derepression and OXA-
1, OXA-31 were more frequent due to the high probability of 
colonization and infection in these patients. In the emergency room, 
the AmpC derepression phenotype was more frequent, which can 
be correlated with the acquisition of the infection in non-associated 
health care areas, that is, this is a community phenotype.
This study shows that multiple resistance phenotypes in a non-
negligible percentage can occur simultaneously and confirms that 
infection with P. aeruginosa is polyclonal; one of the main causes is 
the indiscriminate use of antibiotics at hospital level since there is a 
selection pressure. Therefore, knowing the rates of resistance and 
the institutional phenotype profile allows optimizing the selection of 
antimicrobials in the institution and establishing which antibiotic of 
choice is in each of the services, especially in an empirical manner.
HOMI is a pediatric referral institution in Colombia that handles a 
wide range of highly complex pathologies; there, the characterization 
of P. aeruginosa is essential in the context of rational use of antibiotics 
and to reduce the resistant strains of the institution.
This work has biases derived from secondary sources originated 
by bacterial isolates and, as only single records of the antibiograms 
were analyzed, it is not possible to differentiate between colonization 
and infection. Since the inference is interpreted according to the 
reading of the antibiogram, molecular techniques should be applied 
to confirm the findings.
This study is derived from a thesis that is in the repository of 
Universidad Nacional de Colombia (19).
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